Kevin D. Bunker - Oct 3, 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role: Chief Scientific Officer
Signature: By: /s/ Melissa B. Epperly, Attorney-in-Fact for Kevin D. Bunker
Stock symbol: ZNTL
Transactions as of: Oct 3, 2022
Transactions value $: $0
Form type: 4
Date filed: 10/3/2022, 06:40 PM
Previous filing: Aug 12, 2022
Next filing: Feb 1, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZNTL	Common Stock	Award	$0	+50K	+6.54%	$0.00	814K	Oct 3, 2022	Direct	F1
holding	ZNTL	Common Stock						95K	Oct 3, 2022	See Footnote	F2
holding	ZNTL	Common Stock						350	Oct 3, 2022	As UTMA custodian for sons

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZNTL	Stock Option (Right to Buy)	Award	$0	+50K		$0.00	50K	Oct 3, 2022	Common Stock	50K	$22.21	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") granted by the Issuer under the Zentalis Pharmaceuticals, Inc. 2020 Incentive Award Plan, as amended (the "2020 Plan"). The RSUs will vest over two years: 1/3 of the RSUs will vest on the first anniversary of the date of grant, and the remaining 2/3 of the RSUs will vest on the second anniversary of the date of grant.
F2	Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any.
F3	The options were granted by the Issuer under the 2020 Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer.